RT @MeralElRamahiMD: Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if
Tweet Content
Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if insurance approval was not a factor in those that failed a bDMARD and remain on a cDMARD with high dz activity! @RheumNow @LCalabreseDO @ElaineHusniMD #ACR20 https://t.co/rl1nTqxzKg
Show on Archive Page
On
Display in Search Results
On